Pfizer: FDA extends review of abrocitinib

(CercleFinance.com) - Pfizer announced on Wednesday that the FDA has extended the review period for approval of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in adults and teenagers.


The US health authority says it has now set a target date of early in the third quarter, three months later than originally envisaged.

Last October, the FDA granted the drug priority review for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.

Atopic dermatitis, more commonly known as eczema, is a chronic inflammatory skin disease characterised by dryness, redness, itching and even crusting that progresses in flare-ups and skin irritation.


Copyright (c) 2021 CercleFinance.com. All rights reserved.